ZAI LAB LTD (ZLAB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$26.23-2.85%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ZLAB
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks ZLAB against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress multiple clinical and regulatory milestones for key oncology and immunology programs, including registrational Phase 3 studies and initial human data.
Stated as a priority in 2 of last 2 quarters. Management emphasized advancing multiple global oncology and immunology programs toward key clinical and regulatory milestones in both 2026-Q1 and 2026-Q2. The pipeline progress is consistent with management's stated focus, with ongoing registrational Phase 3 studies and expected data readouts in the second half of 2026, indicating delivering progress on this growth priority.
“The Company advanced multiple global oncology and immunology programs toward key clinical and regulatory milestones, with significant pipeline catalysts expected in the second half of 2026.”
“We continue to accelerate the development of our global pipeline, with numerous clinical trials underway across oncology and immunology.”
Focus on stabilizing product sales in 2026 while laying the foundation for a return to meaningful revenue growth in 2027.
Stated as a priority in 2 of last 2 quarters. Revenue increased from $99.6 million in 2026-Q1 to $106.3 million in 2026-Q2, reflecting sequential growth and stabilization of product sales. Management reiterated expectations to stabilize sales in H2 2026 and return to meaningful growth in 2027, indicating delivering progress on this growth priority.
“In the second half of the year, we expect to further stabilize product sales while laying the foundation for a return to meaningful growth in 2027.”
Continue efforts to streamline organization, optimize resource allocation, and enhance operating efficiency to improve operating income.
Stated as a priority in 2 of last 2 quarters. SG&A expenses were $65.1 million in 2026-Q1 and $72.9 million in 2026-Q2, relatively flat year over year but increased sequentially. Operating income declined from -$69.4 million in 2026-Q1 to -$76.5 million in 2026-Q2. Despite management's efforts to streamline and optimize, operating income remains negative and slightly worsened, indicating limited progress on improving operating income.
Launch new products like KarXT and secure regulatory approvals such as TIVDAK in China to expand commercial footprint.
Stated as a priority in 2 of last 2 quarters. Management reported the successful commercial launch of KarXT in mainland China and regulatory approval of TIVDAK by the NMPA in 2026-Q2, following launch preparations and regulatory review in 2026-Q1. This indicates delivering progress on expanding commercial presence and regulatory milestones in China.
“KarXT successfully launched in mainland China; TIVDAK approved by NMPA for recurrent or metastatic cervical cancer.”
Control operating cash burn and maintain cash and cash equivalents to support operations and growth initiatives.
Stated as a priority in 2 of last 2 quarters. Cash and cash equivalents decreased from $761.3 million in 2026-Q1 to $717.5 million in 2026-Q2, reflecting ongoing cash burn. Operating cash flow improved from -$26.0 million in 2025-Q4 to -$11.9 million in 2026-Q1, indicating some progress in managing cash burn. The trajectory shows limited progress but continued focus on liquidity management.
“Cash and cash equivalents, short-term investments, and current restricted cash totaled $717.5 million as of June 30, 2026.”
Over the trailing year it converted 0.72x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
6 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.
“Commercial business positioned for a return to meaningful growth in 2027.”
“SG&A remained relatively flat year over year, reflecting continued efforts to streamline the organization, optimize resource allocation, and enhance operating efficiency.”
“SG&A expenses were $65.1 million in 2026-Q1, compared to $63.4 million for the same period in 2025.”
“KarXT launch preparations are underway and TIVDAK remains under regulatory review.”
“Cash and cash equivalents, short-term investments, and current restricted cash totaled $761.3 million as of March 31, 2026.”